A blinded, randomized, placebo‐controlled, dose determination trial of lokivetmab (<scp>ZTS</scp>‐00103289), a caninized, anti‐canine <scp>IL</scp>‐31 monoclonal antibody in client owned dogs with atopic dermatitis

Abstract

Lokivetmab (0.5, 2.0 mg/kg) reduced pruritus compared to placebo for at least 1 month. Level and duration of response increased with increasing dose. Further studies are needed to better understand variability in individual responses across a broader population of dogs with AD.